Integra LifeSciences (IART) Misses Q1 EPS by 15c; offers guidance

Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.41, $0.15 worse than the analyst estimate of $0.56. Revenue for the quarter came in at $382.7 million versus the consensus estimate of $411.65 million.

GUIDANCE:

Integra LifeSciences sees Q2 2025 EPS of $0.40-$0.45, versus the consensus of $0.57. Integra LifeSciences sees Q2 2025 revenue of $390-400 million, versus the consensus of $417 million.

Integra LifeSciences sees FY2025 EPS of $2.19-$2.29, versus the consensus of $2.46. Integra LifeSciences sees FY2025 revenue of $1.650-1.715 billion, versus the consensus of $1.679 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Rocket Lab launches U.S. Space Force mission in record 16 hours
• Apollo Private Credit Fund caps redemptions at 5% - Bloomberg